Corticotropin releasing factor receptor antagonists for major depressive disorder
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Major depressive disorder is a serious and common psychiatric illness, and many of the depressive patients benefit from pharmacological treatment. Available antidepressants produce remission in only about 30 -- 40% of the patients. Therefore, new concepts are being explored for the development of innovative antidepressants with higher efficacy. AREAS COVERED: The use of corticotropin releasing factor type 1 (CRF1) receptor antagonists for depression is supported by abundant evidence of target validation, the availability of in vitro and in vivo assays and specific small ligands. Some of these compounds have advanced to clinical studies, with discouraging results so far in depression. This review covers the development of CRF1 receptor antagonists at different stages of the development pipeline of the pharmaceutical industry and its bottlenecks. Most of the available CRF1 receptor antagonists known so far share a common chemical scaffold. We present possible strategies to overcome obstacles in the discovery and development process at the levels of library screenings and clinical studies to find more diverse compounds. EXPERT OPINION: CRF1 receptor antagonists are expected to be beneficial only for those patients with CRF overexpression and the need for tests to identify these individuals is discussed. New technical developments and diagnostic tools might eventually lead to a more successful treatment of major depression with CRF1 receptor antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“5% of the patients, as has been reported for a study with a serotonin reuptake inhibitor [5].”
BackgroundEpidemiology of women and depression
Kessler, R. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00426-3 · Cited by 2,006 · cited 1×
“Major depression is a frequent affective disorder with lifetime prevalence up to 15% in the industrialized world [2,3].”
BackgroundThe link between childhood trauma and depression: insights from HPA axis studies in humans
Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.03.008 · Cited by 1,704
Nemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485 · cited 4×
“4 The need for patient stratification for CRF1 receptor antagonist treatment A careful analysis of the data on CRF levels in the cerebrospinal fluid of depressive patients in comparison to normal subjects shows that among the depressive population some individuals have increased amounts while some others are within th…”
BackgroundInfluentialThe role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378
Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment
Pariante, C. M., & Miller, A. H. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01088-x · Cited by 1,147 · cited 1×
“An impaired regulation of the HPA axis is the most robust laboratory finding in patients with major depression [13,26-28].”
BackgroundJACOBI, F., WITTCHEN, H.-U., HÖLTING, C., HÖFLER, M., PFISTER, H., MÜLLER, N., & LIEB, R. (2004) · Psychological Medicine · doi:10.1017/s0033291703001399 · Cited by 1,097 · cited 1×
“Major depression is a frequent affective disorder with lifetime prevalence up to 15% in the industrialized world [2,3].”
BackgroundBinder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977 · cited 4×
“There is also a strong correlation between FKBP5 mRNA expression in peripheral lymphocytes and serum cortisol levels in individuals carrying the genotypes associated with fast response to antidepressants than the other genotypes, indicating an altered GR/FKBP5 feedback mechanism associated with these genotypes [10,122…”
BackgroundSelf-citationLewis, K., Li, C., Perrin, M. H., Blount, A., Kunitake, K., Donaldson, C., Vaughan, J., Reyes, T. M., Gulyas, J., Fischer, W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121165198 · Cited by 925 · cited 4×
“They only share ~ 30 -- 40% homology with r/hCRF and urocortin, but the homology between mouse and human is 76% for SRP/ UCN2 and 90% for SCP/UCN3.”
BackgroundInfluentialTimpl, P., Spanagel, R., Sillaber, I., Kresse, A., Reul, J. M. H. M., Stalla, G. K., Blanquet, V., Steckler, T., Holsboer, F., & Wurst, W. (1998) · Nature Genetics · doi:10.1038/520 · Cited by 919 · cited 2×
“The CRF1 receptor-deficient mice, on the other hand, exhibit low plasma ACTH and corticosterone levels, reduced stress response and very low anxiety-like behavior [75,76].”
BackgroundResultSelf-citation
Cited by
Wu, G., Feder, A., Cohen, H., Kim, J. J., Calderon, S., Charney, D. S., & Mathé, A. A. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00010 · Cited by 726
Key role of CRF in the skin stress response system
Slominski, A. T., Zmijewski, M. A., Zbytek, B., Tobin, D. J., Theoharides, T. C., & Rivier, J. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1092 · Cited by 400
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Role of neuropeptides in anxiety, stress, and depression: From animals to humans
Kormos, V., & Gaszner, B. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.10.014 · Cited by 329
The Corticotropin-Releasing Factor Family: Physiology of the Stress Response
Deussing, J. M., & Chen, A. (2018) · Physiological Reviews · doi:10.1152/physrev.00042.2017 · Cited by 260
Metadata
- Authors
- Paez-Pereda, M., Hausch, F., & Holsboer, F.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2011-03-14
- Volume
- 20
- Issue
- 4
- Pages
- 519-535
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2059784555
- Cited by
- 58
- References
- 26
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Corticotropin releasing factor receptor antagonists for major depressive disorder. https://app.cochat.ai/papers/10.1517/13543784.2011.565330
- The paper
- Paez-Pereda, M., Hausch, F., & Holsboer, F. (2011). Corticotropin releasing factor receptor antagonists for major depressive disorder. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.2011.565330
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.